NYSE:RDY - Dr. Reddy's Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $71.71
  • Forecasted Upside: 20.11 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$59.70
▼ -1.74 (-2.83%)

This chart shows the closing price for RDY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dr. Reddy's Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDY

Analyst Price Target is $71.71
▲ +20.11% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Dr. Reddy's Laboratories in the last 3 months. The average price target is $71.71, with a high forecast of $80.00 and a low forecast of $63.41. The average price target represents a 20.11% upside from the last price of $59.70.

This chart shows the closing price for RDY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Dr. Reddy's Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/1/2021BarclaysBoost Price TargetOverweight$78.00 ➝ $80.00Low
7/27/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral$63.41Low
5/17/2021BarclaysReiterated RatingBuyLow
2/3/2021InvestecUpgradeHold ➝ BuyMedium
2/2/2021BarclaysUpgradeEqual Weight ➝ Overweight$56.00 ➝ $70.00N/A
9/18/2020Bank of AmericaUpgradeNeutral ➝ BuyLow
9/18/2020InvestecUpgradeSell ➝ HoldHigh
7/30/2020BarclaysBoost Price TargetEqual Weight$45.00 ➝ $53.00Low
4/21/2020Nomura InstinetReiterated RatingBuyMedium
1/9/2020CitigroupUpgradeSell ➝ BuyMedium
11/4/2019Bank of AmericaDowngradeBuy ➝ NeutralMedium
9/4/2019Credit Suisse GroupUpgradeUnderperform ➝ OutperformLow
7/1/2019MacquarieUpgradeNeutral ➝ OutperformLow
6/20/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ HoldLow
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$39.00Low
5/20/2019Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
2/4/2019CL KingUpgradeNeutral ➝ BuyLow
1/17/2019CitigroupDowngradeNeutral ➝ SellLow
11/1/2017Jefferies Financial GroupLower Price TargetUnderperform$31.62 ➝ $30.51N/A
9/21/2017Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
9/3/2017Jefferies Financial GroupReiterated RatingSell$31.62Medium
8/31/2017CLSAUpgradeUnderperform ➝ OutperformHigh
7/28/2017CLSADowngradeUnderperform ➝ SellLow
5/15/2017Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldHigh
(Data available from 1/22/2017 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/23/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/22/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Dr. Reddy's Laboratories logo
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Read More

Today's Range

Now: $59.70
Low: $59.54
High: $60.95

50 Day Range

MA: $62.38
Low: $59.50
High: $65.42

52 Week Range

Now: $59.70
Low: $57.54
High: $75.50

Volume

85,349 shs

Average Volume

104,607 shs

Market Capitalization

$9.93 billion

P/E Ratio

34.31

Dividend Yield

0.46%

Beta

0.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Dr. Reddy's Laboratories?

The following Wall Street research analysts have issued research reports on Dr. Reddy's Laboratories in the last year: Barclays PLC, Credit Suisse Group AG, Investec, and Zacks Investment Research.
View the latest analyst ratings for RDY.

What is the current price target for Dr. Reddy's Laboratories?

2 Wall Street analysts have set twelve-month price targets for Dr. Reddy's Laboratories in the last year. Their average twelve-month price target is $71.71, suggesting a possible upside of 20.1%. Barclays PLC has the highest price target set, predicting RDY will reach $80.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $63.41 for Dr. Reddy's Laboratories in the next year.
View the latest price targets for RDY.

What is the current consensus analyst rating for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RDY will outperform the market and that investors should add to their positions of Dr. Reddy's Laboratories.
View the latest ratings for RDY.

What other companies compete with Dr. Reddy's Laboratories?

How do I contact Dr. Reddy's Laboratories' investor relations team?

Dr. Reddy's Laboratories' physical mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company's listed phone number is 914049002900 and its investor relations email address is [email protected] The official website for Dr. Reddy's Laboratories is www.drreddys.com.